As inhibition of the PI3K/AKT pathway may partially restore sensitivity to cisplatinum in cancer cells [43], this finding also explains the reason why afatinib could reverse the resistance to cisplatinum, which is not a substrate of ABCB1 (Table 1). This evidence concerns the gene AKT1 and cancer.